Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity.

Literature DB >> 25666155

Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity.

Diane N Singhroy¹, Mark A Wainberg², Thibault Mesplède³.

Abstract

We investigated the effect of combining the dolutegravir-specific R263K integrase resistance substitution with either M184I or M184V, two reverse transcriptase drug resistance substitutions that are frequently detected in individuals failing therapeutic regimens containing either lamivudine or emtricitabine. The presence of R263K and M184I/V in a single virus resulted in substantial further decreases in the viral replicative capacity compared to that in the presence of single substitutions alone.

Entities: Chemical Disease Mutation

Mesh：

Substances：

Year: 2015 PMID： 25666155 PMCID： PMC4394770 DOI： 10.1128/AAC.05181-14

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

34 in total

1. OpenEpi: a web-based epidemiologic and statistical calculator for public health.

Authors: Kevin M Sullivan; Andrew Dean; Minn Minn Soe
Journal: Public Health Rep Date: 2009 May-Jun Impact factor: 2.792

2. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.

Authors: David A Wohl; Calvin Cohen; Joel E Gallant; Anthony Mills; Paul E Sax; Edwin Dejesus; Andrew Zolopa; Hui C Liu; Andrew Plummer; Kirsten L White; Andrew K Cheng; Martin S Rhee; Javier Szwarcberg
Journal: J Acquir Immune Defic Syndr Date: 2014-03-01 Impact factor: 3.731

3. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors: A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal: J Virol Date: 1986-08 Impact factor: 5.103

4. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.

Authors: Thibault Mesplède; Nathan Osman; Melissa Wares; Peter K Quashie; Said Hassounah; Kaitlin Anstett; Yingshan Han; Diane N Singhroy; Mark A Wainberg
Journal: J Antimicrob Chemother Date: 2014-06-10 Impact factor: 5.790

5. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.

Authors: M D Miller; N A Margot; K Hertogs; B Larder; V Miller
Journal: Nucleosides Nucleotides Nucleic Acids Date: 2001 Apr-Jul Impact factor: 1.381

6. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors: E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal: J Virol Date: 1998-04 Impact factor: 5.103

7. Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1.

Authors: Emily J Platt; Miroslawa Bilska; Susan L Kozak; David Kabat; David C Montefiori
Journal: J Virol Date: 2009-05-27 Impact factor: 5.103

8. Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins.

Authors: W Keulen; C Boucher; B Berkhout
Journal: Antiviral Res Date: 1996-06 Impact factor: 5.970

9. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure.

Authors: Thibault Mesplède; Peter K Quashie; Nathan Osman; Yingshan Han; Diane N Singhroy; Yolanda Lie; Christos J Petropoulos; Wei Huang; Mark A Wainberg
Journal: Retrovirology Date: 2013-02-22 Impact factor: 4.602

10. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness.

Authors: Melissa Wares; Thibault Mesplède; Peter K Quashie; Nathan Osman; Yingshan Han; Mark A Wainberg
Journal: Retrovirology Date: 2014-01-17 Impact factor: 4.602

8 in total

1. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.

Authors: Jiaming Liang; Thibault Mesplède; Maureen Oliveira; Kaitlin Anstett; Mark A Wainberg
Journal: J Virol Date: 2015-08-26 Impact factor: 5.103

2. Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.

Authors: Kristen N Andreatta; Michael D Miller; Kirsten L White
Journal: Antimicrob Agents Chemother Date: 2015-11-16 Impact factor: 5.191

Review 3. Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence.

Authors: Thibault Mesplède; Mark A Wainberg
Journal: Viruses Date: 2015-07-07 Impact factor: 5.048

4. Tribute to Mark Wainberg.

Authors: Eric J Arts; Anne Gatignol; Andrew J Mouland; Chen Liang; Matthias Götte; Hugo Soudeyns
Journal: Retrovirology Date: 2017-06-28 Impact factor: 4.602

5. Case Report: Emergent Resistance in a Treatment-Naive Person With Human Immunodeficiency Virus Under Bictegravir-Based Therapy.

Authors: Nicholas Chamberlain; Leandro Mena; James Benjamin Brock
Journal: Open Forum Infect Dis Date: 2021-06-04 Impact factor: 3.835